Peptide-Enhanced DNA Origami Nanostructures Delivered by Nebulizer Treat Acute Lung Injury in Mice
Cell-penetrating R9 peptide-modified DNA origami nanostructures, delivered via nebulizer directly to the lungs, reduced dangerous inflammation in alveolar macrophages and alleviated acute lung injury in mice.
Quick Facts
What This Study Found
R9 peptide-modified triangular DNA origami nanostructures, delivered by nebulization, effectively targeted alveolar macrophages, scavenged ROS, promoted M2 polarization, and reduced lung inflammation in an ALI mouse model.
Key Numbers
R9 peptide-modified triangular DNA origami (tDONs-R9); nebulized delivery to deep lung; targeted alveolar macrophages.
How They Did This
Designed and synthesized tDONs-R9 using DNA origami technology with R9 CPP modification. Tested macrophage uptake and polarization in vitro, then evaluated therapeutic efficacy via nebulized inhalation in an LPS-induced ALI mouse model. Measured ROS levels, cytokine expression, and neutrophil infiltration.
Why This Research Matters
Acute lung injury and ARDS have limited treatment options and high mortality rates, as highlighted during COVID-19. A nebulizable therapy that directly targets the lung macrophages driving inflammation — and can scavenge the damaging oxidants — could provide early intervention before irreversible lung damage occurs.
The Bigger Picture
This study sits at the intersection of three cutting-edge technologies: DNA origami nanotechnology, cell-penetrating peptides, and inhaled drug delivery. The combination creates a platform that could extend beyond ALI to other inflammatory lung diseases like COPD, asthma, and pulmonary fibrosis. The programmable nature of DNA origami means the nanostructures could potentially be loaded with additional therapeutic agents.
What This Study Doesn't Tell Us
Mouse study using LPS-induced ALI — this model doesn't perfectly replicate human ALI/ARDS. Manufacturing DNA origami at clinical scale remains a significant challenge. Long-term safety of DNA nanostructures accumulating in lung tissue is unknown. Only one disease model and one time point were tested.
Questions This Raises
- ?Can DNA origami nanostructures be produced at the scale and consistency needed for clinical use?
- ?How do tDONs-R9 perform in more clinically relevant ALI models, such as ventilator-induced or sepsis-induced lung injury?
- ?Could this platform be adapted to carry additional drugs or anti-inflammatory agents for enhanced therapeutic effect?
Trust & Context
- Key Stat:
- Enhanced macrophage uptake + M2 polarization R9 CPP modification drove preferential uptake by alveolar macrophages and shifted them from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype, breaking the inflammation cascade
- Evidence Grade:
- Preliminary — single animal study demonstrating proof-of-concept in one mouse ALI model. Promising results but far from clinical application.
- Study Age:
- Published in 2024 in Nano Letters, a top-tier nanotechnology journal.
- Original Title:
- Nebulized Inhalation of Peptide-Modified DNA Origami To Alleviate Acute Lung Injury.
- Published In:
- Nano letters, 24(20), 6102-6111 (2024)
- Authors:
- Wang, Haiyan(2), Jiao, Yunfei, Ma, Shuaijing, Li, Zhuoting, Gong, Jintao, Jiang, Qiao, Shang, Yingxu, Li, Hongling, Li, Jing, Li, Na, Zhao, Robert Chunhua, Ding, Baoquan
- Database ID:
- RPEP-09471
Evidence Hierarchy
Frequently Asked Questions
What is DNA origami and how can it treat lung disease?
DNA origami is a technique where long strands of DNA are folded into precise 2D or 3D shapes — like molecular paper folding. These tiny structures (about 1/1000th the width of a human hair) can naturally scavenge reactive oxygen species (the damaging molecules that drive lung inflammation). By modifying them with cell-penetrating peptides, researchers can direct them into the immune cells causing the inflammation, where they mop up oxidants and calm the immune response.
Why use a nebulizer instead of an injection?
Nebulizers turn liquid medicine into a fine mist that's inhaled directly into the lungs, delivering the treatment exactly where it's needed. For lung diseases, this means much higher drug concentrations reach the target tissue compared to injection, where the drug gets diluted throughout the entire body. It also means lower total doses and fewer systemic side effects.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09471APA
Wang, Haiyan; Jiao, Yunfei; Ma, Shuaijing; Li, Zhuoting; Gong, Jintao; Jiang, Qiao; Shang, Yingxu; Li, Hongling; Li, Jing; Li, Na; Zhao, Robert Chunhua; Ding, Baoquan. (2024). Nebulized Inhalation of Peptide-Modified DNA Origami To Alleviate Acute Lung Injury.. Nano letters, 24(20), 6102-6111. https://doi.org/10.1021/acs.nanolett.4c01222
MLA
Wang, Haiyan, et al. "Nebulized Inhalation of Peptide-Modified DNA Origami To Alleviate Acute Lung Injury.." Nano letters, 2024. https://doi.org/10.1021/acs.nanolett.4c01222
RethinkPeptides
RethinkPeptides Research Database. "Nebulized Inhalation of Peptide-Modified DNA Origami To Alle..." RPEP-09471. Retrieved from https://rethinkpeptides.com/research/wang-2024-nebulized-inhalation-of-peptidemodified
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.